Loretta Mak on Muck Rack

Loretta Mak

As seen in: The Lancet, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Loretta

Contact Loretta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies

|
By Eero Poukka, Caitríona Murphy, Loretta Mak, Tim K. Tsang
| medRxiv
EP is involved in an estate that holds shares of Astra Zeneca. BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche and Sanofi Pasteur. SGS reports honoraria from CSL Seqirus, Evo Health, Moderna, Novavax and Pfizer. The authors report no other potential conflicts of interest. This project was supported by the Health and Medical Research Fund, Health Bureau, The Government of the Hong Kong Special Administrative Region (grant no.
Open in Who Shared View Duplicates (20) Issue with article?

Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness

|
By Caitríona Murphy, Loretta Mak, Eero Poukka, Malik Peiris
| medRxiv
BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. The authors report no other potential conflicts of interest. This research was supported by the Health and Medical Research Fund, Health Bureau, The Government of the Hong Kong Special Administrative Region (grant no. INF-HKU-3). BJC is supported by the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government.
Open in Who Shared View Duplicates (132) Issue with article?

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

|
By Gabriel M Leung, New Territories, Benjamin J Cowling, Loretta Mak
| The Lancet Verified
1 Perera RA Mok CK Tsang OT et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020; 252000421 We report here comparative data on SARS-CoV-2 vaccine immunogenicity in health-care workers in Hong Kong who received either the BNT162b2 vaccine (Comirnaty; Fosun–BioNTech) or the inactivated virus (vero cell) vaccine (Coronavac; Sinovac).
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified